Under current rules, if a challenger is found guilty of infringement, it is liable to pay as much as three times the sales of the drug under dispute for the period the generic variant was in the market. This poses a big risk for generic challengers.
The amendments will value such fines based on the value addition that the patent owner can demonstrate in its product over other existing drugs.
It is unclear when the Senate will vote on the proposed legislation.
Tags - Find More Articles On: